Malignant Pleural Mesothelioma Market Positioned for Growth Through 2034, DelveInsight Finds

The Malignant Pleural Mesothelioma market was valued at approximately USD 250 million in the 7MM in 2025 and is projected to experience steady growth during the forecast period (2025–2034). DelveInsight's comprehensive market research provides critical insights into market trends, enabling stakeholders to understand growth drivers, emerging opportunities, and potential challenges within the Malignant Pleural Mesothelioma landscape. By analyzing historical data, current market dynamics, and future projections, DelveInsight equips pharmaceutical companies, investors, and healthcare professionals with actionable intelligence to make informed strategic decisions, identify investment opportunities, optimize product positioning, and plan research and development initiatives effectively.

The Malignant Pleural Mesothelioma market is increasingly guided by immunotherapy-based strategies. Among currently marketed drugs, OPDIVO (Nivolumab) + YERVOY (Ipilimumab) held the largest market share in 2024 across the 7MM. More recently, KEYTRUDA (pembrolizumab) in combination with pemetrexed and platinum chemotherapy has been approved as a first-line treatment option, expanding the therapeutic landscape for patients with unresectable advanced or metastatic Malignant Pleural Mesothelioma.

In 2024, the total number of mesothelioma cases across the 7MM was over 11,000. However, this figure is expected to decline by 2034, reflecting declining incidence trends in most regions due to historical asbestos exposure patterns and stricter regulations.

DelveInsight's report, "Malignant Pleural Mesothelioma Market Insights, Epidemiology, and Market Forecast- 2034", provides a comprehensive analysis of the Malignant Pleural Mesothelioma landscape. The report delivers detailed insights into the disease, including historical and projected epidemiology, helping stakeholders understand the prevalence, incidence, and patient demographics across key regions. Additionally, it examines Malignant Pleural Mesothelioma market dynamics, offering a thorough assessment of current and emerging market trends, treatment patterns, and therapeutic developments. The analysis spans major markets, including the United States, EU4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan, equipping decision-makers with actionable intelligence for strategic planning, investment, and research initiatives.

To know in detail about the Malignant Pleural Mesothelioma market outlook, drug uptake, treatment scenario and epidemiology trends, download the Malignant Pleural Mesothelioma Market Insights Report

Some of the key facts of the Malignant Pleural Mesothelioma Market Report:

• Key Malignant Pleural Mesothelioma Companies: Merck, Bristol-Myers Squibb, AstraZeneca, Polaris Pharmaceuticals, Amphera BV, RS Oncology, Sellas Life Sciences Group, CRISPR Therapeutics AG, Vivace Therapeutics, NuCana plc, A2 Biotherapeutics, and Tango Therapeutics, among others.
• Key Malignant Pleural Mesothelioma Therapies: KEYTRUDA (pembrolizumab), OPDIVO (nivolumab), YERVOY (ipilimumab), Pegargiminase (ADI-PEG 20), MesoPher, rAd-IFN, and others.
• The Malignant Pleural Mesothelioma market is expected to experience steady growth driven by the advancement of immunotherapies and targeted therapies. Furthermore, launching various multiple-stage Malignant Pleural Mesothelioma pipeline products will significantly impact market dynamics during the forecast period.

Malignant Pleural Mesothelioma Overview

Malignant Pleural Mesothelioma (MPM) is an aggressive cancer that develops from mesothelial cells lining the pleura and is strongly associated with long-term asbestos exposure. The disease is marked by rapid progression and a high mortality rate, primarily affecting older men decades after initial exposure. Malignant Pleural Mesothelioma is characterized by significant tumor heterogeneity, which contributes to resistance to treatment and poses considerable management challenges. Early detection remains limited, with most patients diagnosed at advanced stages when treatment options are constrained.

Key Trends in Malignant Pleural Mesothelioma Therapeutics Market:

• Immunotherapy Dominance: Growing adoption of immune checkpoint inhibitors such as PD-1/PD-L1 inhibitors as first-line and combination treatments for advanced Malignant Pleural Mesothelioma
• Combination Therapy Strategies: Enhanced efficacy through combining immunotherapy with traditional chemotherapy and novel targeted therapies
• Perioperative Immunotherapy: Development of neoadjuvant and adjuvant immunotherapy approaches combined with surgery for operable mesothelioma
• Gene Therapy Innovation: Introduction of adenovirus-delivered gene therapies and other advanced biological approaches
• Precision Medicine and Biomarker Testing: Enhanced molecular diagnostics to identify patient populations most likely to benefit from specific therapies
• Improved Diagnostic Methods: Advancement in liquid biopsy technologies and circulating tumor DNA (ctDNA) monitoring for residual disease detection

Malignant Pleural Mesothelioma Epidemiology

The report on Malignant Pleural Mesothelioma epidemiology provides a comprehensive analysis of the disease's prevalence, incidence, and patient demographics. It includes age- and gender-specific distribution, regional and global trends, and data on disease burden and projections. The report highlights that malignant pleural mesothelioma accounts for approximately 75% of all mesothelioma cases. In the United States, the SEER Program database estimates approximately 2,500 to 3,000 cases annually, predominantly affecting elderly men, with incidence plateauing since 2000-2005 and showing a subsequent decline. In Japan, mesothelioma deaths have increased, with approximately 1,400 deaths reported in 2012, indicating a different epidemiological pattern than Western countries.

Malignant Pleural Mesothelioma Epidemiology Segmentation

The Malignant Pleural Mesothelioma market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total Incident Cases of Malignant Pleural Mesothelioma
• Gender-specific Incident Cases of Malignant Pleural Mesothelioma
• Age-specific Incident Cases of Malignant Pleural Mesothelioma
• Histology-specific Incident Cases of Malignant Pleural Mesothelioma
• Stage-specific Incident Cases of Malignant Pleural Mesothelioma
• Line-wise Treated Cases of Malignant Pleural Mesothelioma

Download the report to understand which factors are driving Malignant Pleural Mesothelioma epidemiology trends @ Malignant Pleural Mesothelioma Epidemiology Forecast

Recent Developments In The Malignant Pleural Mesothelioma Treatment Landscape:

• In October 2025, the FDA granted Fast Track designation to VT3989 for the treatment of unresectable malignant pleural or nonpleural mesothelioma. VT3989 is in clinical trials recruiting patients in the US and Australia, with a study completion anticipated by mid-2027.
• In September 2025, researchers from Johns Hopkins Kimmel Cancer Centre published findings in Nature Medicine demonstrating that perioperative combination immunotherapy using nivolumab alone or in combination with ipilimumab, followed by surgery and postoperative nivolumab, was feasible and safe in patients with operable mesothelioma. Over 80% of patients successfully underwent surgery within the planned window after receiving neoadjuvant immunotherapy. Patients treated with the combination regimen lived a median of 28.6 months, with nearly 36% alive and recurrence-free at follow-up. The study also demonstrated that patients with undetectable circulating tumor DNA (ctDNA) levels or those showing a 95% or greater drop in ctDNA during treatment experienced significantly longer event-free and overall survival.
• In September 2024, the U.S. Food and Drug Administration (FDA) approved KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, in combination with pemetrexed and platinum chemotherapy for the first-line treatment of adult patients with unresectable advanced or metastatic malignant pleural mesothelioma (MPM). 
• Ferring Ventures Limited is conducting a Phase 3 clinical trial assessing the efficacy and safety of rAd-IFN, an adenovirus-delivered interferon alpha-2b gene therapy, in combination with celecoxib and gemcitabine for treating malignant pleural mesothelioma. The trial involves intrapleural administration of rAd-IFN and is expected to complete by April 2026.
• Multiple clinical trials are actively recruiting mesothelioma patients across the U.S., including studies evaluating emerging immunotherapy combinations, cancer vaccine approaches, Tumor Treating Fields technology, and advanced surgical techniques.

Malignant Pleural Mesothelioma Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of potential drugs recently launched in the Malignant Pleural Mesothelioma market or expected to get launched during the study period. The analysis covers Malignant Pleural Mesothelioma market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind their maximal use. Additionally, it compares the drugs based on market share.

The report also covers the Malignant Pleural Mesothelioma Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies. Download the report to get the complete overview.

Malignant Pleural Mesothelioma Therapies and Key Companies

• KEYTRUDA (pembrolizumab): Merck
• OPDIVO (nivolumab): Bristol-Myers Squibb
• YERVOY (ipilimumab): Bristol-Myers Squibb
• Pegargiminase (ADI-PEG 20): Polaris Pharmaceuticals
• MesoPher (immunotherapy): Amphera BV
• rAd-IFN (gene therapy): Ferring Ventures Limited
• Thiostrepton: RS Oncology
• CAR T-cell therapies: Multiple developers
• TEAD inhibitors: Multiple developers
• Cancer vaccines: Multiple developers

To know more about Malignant Pleural Mesothelioma companies working in the treatment market and their competitive advantages, visit @ Malignant Pleural Mesothelioma Clinical Trials and Therapeutic Assessment

Malignant Pleural Mesothelioma Market Drivers

• Introduction of innovative immunotherapies improving survival outcomes and expanding treatment options.
• Rising prevalence of mesothelioma cases in certain regions driving demand for effective therapies.
• Advancement in perioperative and multimodal treatment approaches combining surgery with immunotherapy.
• Development of gene therapies and novel biological approaches offering new treatment paradigms.
• Improved diagnostic capabilities using biomarkers and liquid biopsy technologies enabling precision medicine.
• Growing investment in research and development initiatives by major pharmaceutical companies.
• Expanding clinical trial pipeline with multiple candidates in advanced development stage.

Malignant Pleural Mesothelioma Market Barriers

• Limited eligible patient population due to declining mesothelioma incidence in most 7MM regions.
• High cost of innovative therapies limiting patient access and affecting market penetration.
• Significant economic burden associated with treatment and disease management.
• Complexity of treatment approaches requiring specialized surgical expertise and multimodal therapy coordination.
• Failures and discontinuation of emerging therapies impacting market growth.
• Market access and reimbursement issues in certain regions.
• Shortage of healthcare specialists experienced in mesothelioma management.
• Underdiagnosis and underreporting of cases due to disease rarity and limited awareness.

Scope of the Malignant Pleural Mesothelioma Market Report

• Study Period: 2020–2034
• Coverage: 7MM [The United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]
• Key Malignant Pleural Mesothelioma Companies: Merck, Bristol-Myers Squibb, AstraZeneca, Polaris Pharmaceuticals, Amphera BV, RS Oncology, Sellas Life Sciences Group, CRISPR Therapeutics AG, Vivace Therapeutics, NuCana plc, A2 Biotherapeutics, and Tango Therapeutics
• Key Malignant Pleural Mesothelioma Therapies: KEYTRUDA (pembrolizumab), OPDIVO (nivolumab), YERVOY (ipilimumab), Pegargiminase (ADI-PEG 20), MesoPher, rAd-IFN, and others
• Malignant Pleural Mesothelioma Therapeutic Assessment: Malignant Pleural Mesothelioma current marketed and Malignant Pleural Mesothelioma emerging therapies
• Malignant Pleural Mesothelioma Market Dynamics: Malignant Pleural Mesothelioma market drivers and Malignant Pleural Mesothelioma market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Malignant Pleural Mesothelioma Unmet Needs, KOL's views, Analyst's views, Malignant Pleural Mesothelioma Market Access and Reimbursement